Roberts Capital Advisors LLC Makes New Investment in Merck & Co., Inc. $MRK

Roberts Capital Advisors LLC acquired a new position in Merck & Co., Inc. (NYSE:MRK) during the third quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 6,321 shares of the company’s stock, valued at approximately $531,000.

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in the business. Charles Schwab Investment Management Inc. lifted its holdings in shares of Merck & Co., Inc. by 9.4% in the 2nd quarter. Charles Schwab Investment Management Inc. now owns 53,865,466 shares of the company’s stock valued at $4,263,991,000 after buying an additional 4,636,183 shares during the period. DLD Asset Management LP lifted its holdings in Merck & Co., Inc. by 30.1% in the third quarter. DLD Asset Management LP now owns 47,500,000 shares of the company’s stock valued at $3,986,675,000 after acquiring an additional 11,000,000 shares during the period. Norges Bank acquired a new position in Merck & Co., Inc. in the second quarter valued at approximately $2,858,570,000. Franklin Resources Inc. boosted its position in Merck & Co., Inc. by 23.5% in the 2nd quarter. Franklin Resources Inc. now owns 27,032,601 shares of the company’s stock worth $2,139,901,000 after purchasing an additional 5,135,748 shares in the last quarter. Finally, Fisher Asset Management LLC grew its stake in shares of Merck & Co., Inc. by 2.3% during the 2nd quarter. Fisher Asset Management LLC now owns 25,013,697 shares of the company’s stock worth $1,980,084,000 after purchasing an additional 567,900 shares during the period. 76.07% of the stock is currently owned by institutional investors and hedge funds.

Insiders Place Their Bets

In other news, EVP David Michael Williams sold 5,000 shares of the firm’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.91, for a total value of $609,550.00. Following the transaction, the executive vice president directly owned 30,838 shares of the company’s stock, valued at approximately $3,759,460.58. This trade represents a 13.95% decrease in their ownership of the stock. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, insider Johannes Jacobus Oosthuizen sold 15,000 shares of the company’s stock in a transaction dated Friday, February 6th. The shares were sold at an average price of $121.87, for a total transaction of $1,828,050.00. Following the sale, the insider directly owned 21,197 shares of the company’s stock, valued at approximately $2,583,278.39. This represents a 41.44% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last three months, insiders sold 320,176 shares of company stock valued at $38,281,735. Corporate insiders own 0.13% of the company’s stock.

Wall Street Analyst Weigh In

Several equities analysts recently issued reports on MRK shares. Citigroup boosted their target price on shares of Merck & Co., Inc. from $115.00 to $120.00 and gave the company a “neutral” rating in a research note on Wednesday, February 4th. Wall Street Zen lowered shares of Merck & Co., Inc. from a “buy” rating to a “hold” rating in a research note on Saturday, February 28th. Bank of America upped their price target on Merck & Co., Inc. from $105.00 to $120.00 and gave the stock a “buy” rating in a report on Monday, December 15th. UBS Group increased their price target on Merck & Co., Inc. from $105.00 to $130.00 and gave the stock a “buy” rating in a research report on Wednesday, January 7th. Finally, The Goldman Sachs Group raised their price objective on Merck & Co., Inc. from $92.00 to $120.00 and gave the company a “buy” rating in a report on Tuesday, December 2nd. One analyst has rated the stock with a Strong Buy rating, ten have issued a Buy rating, six have assigned a Hold rating and one has given a Sell rating to the company. According to MarketBeat.com, the stock has a consensus rating of “Moderate Buy” and an average target price of $125.88.

More Merck & Co., Inc. News

Here are the key news stories impacting Merck & Co., Inc. this week:

• Positive Sentiment: Positive late‑stage clinical results across oncology and HIV programs — Phase 3 data for KEYTRUDA and WELIREG showed improved survival/expanded indications in kidney, ovarian and bladder cancer, and Merck highlighted progress on its DOR/ISL HIV program; these outcomes support revenue growth potential from high‑margin specialty drugs. Merck Trial Wins Shape Oncology And HIV Prospects For Investors
• Positive Sentiment: Recent earnings and guidance remain supportive — Merck posted an EPS beat and set FY2026 guidance, which underpins expectations for profitability and cash generation that fund R&D, buybacks, and dividends. (Earnings referenced from Merck’s Feb results.)
• Neutral Sentiment: Broader market reports note expanding markets for several of Merck’s products (neuroendocrine carcinoma, vaccines like Ervebo, M‑M‑R II, and fertility drug Elonva); these reports signal longer‑term TAM expansion but are not near‑term catalysts by themselves. Neuroendocrine Carcinoma Market Poised for Significant Growth Ervebo (Merck & Co) Market Research Report 2026 M-M-R II (Merck & Co) Market Research Report 2026 Elonva (Merck & Co) Market Research Report 2026
• Neutral Sentiment: Short‑term price momentum: recent coverage noted MRK moving higher within the S&P 500 and outperforming the market on some sessions — useful context for market positioning but not a fundamental change. Merck & Co. Moves Higher Within S&P 500 Index Amid Gains Merck (MRK) Rises Higher Than Market: Key Facts
• Negative Sentiment: Analyst caution on Winrevair — RBC flagged that Winrevair needs to show at least a 20‑meter improvement on the 6‑minute walk test to build confidence; failure to meet clinically meaningful thresholds could weigh on sentiment for that respiratory program. Merck’s Winrevair Must Show Walk Distance Improvement to Build Confidence, RBC Says

Merck & Co., Inc. Trading Down 0.7%

MRK stock opened at $116.21 on Thursday. Merck & Co., Inc. has a 12-month low of $73.31 and a 12-month high of $125.14. The business’s 50-day moving average is $114.86 and its 200 day moving average is $99.26. The company has a current ratio of 1.54, a quick ratio of 1.30 and a debt-to-equity ratio of 0.89. The stock has a market cap of $287.32 billion, a price-to-earnings ratio of 15.96, a PEG ratio of 2.27 and a beta of 0.27.

Merck & Co., Inc. (NYSE:MRK) last announced its earnings results on Tuesday, February 3rd. The company reported $2.04 EPS for the quarter, beating analysts’ consensus estimates of $2.01 by $0.03. Merck & Co., Inc. had a return on equity of 44.57% and a net margin of 28.08%.The business had revenue of $16.40 billion during the quarter, compared to analysts’ expectations of $16.19 billion. During the same quarter in the prior year, the firm earned $1.72 earnings per share. The business’s revenue was up 5.0% compared to the same quarter last year. Merck & Co., Inc. has set its FY 2026 guidance at 5.000-5.150 EPS. On average, sell-side analysts anticipate that Merck & Co., Inc. will post 9.01 EPS for the current fiscal year.

Merck & Co., Inc. Dividend Announcement

The firm also recently announced a quarterly dividend, which will be paid on Tuesday, April 7th. Stockholders of record on Monday, March 16th will be issued a dividend of $0.85 per share. The ex-dividend date of this dividend is Monday, March 16th. This represents a $3.40 dividend on an annualized basis and a dividend yield of 2.9%. Merck & Co., Inc.’s dividend payout ratio is presently 46.70%.

Merck & Co., Inc. Company Profile

Merck & Co, Inc is a global biopharmaceutical company engaged in the discovery, development, manufacture and marketing of prescription medicines, vaccines, biologic therapies and animal health products. Its portfolio spans multiple therapeutic areas with a particular emphasis on oncology, vaccines and infectious disease, as well as therapies for metabolic and chronic conditions. Among its well-known products are the cancer immunotherapy Keytruda (pembrolizumab) and the human papillomavirus vaccine Gardasil; the company also markets a range of medicines and vaccines for veterinary use through Merck Animal Health.

Founded in the late 19th century as the U.S.